<DOC>
	<DOCNO>NCT01684891</DOCNO>
	<brief_summary>This single-center , open label , multiple dose study investigate pharmacokinetics RG1662 give twice daily 28 day , addition , excretion metabolism [ 13C ] -labeled IV microdoses oral [ 14C ] -labeled dose RG1662 healthy male volunteer . The anticipated time study treatment 4 week .</brief_summary>
	<brief_title>A 28-Day Pharmacokinetics Study RG1662 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male volunteer Volunteers surgically sterilize intend father child future Absence evidence active chronic disease follow detailed medical surgical history , complete physical examination include vital sign , 12lead ECG , hematology , blood chemistry , serology urinalysis Body mass index ( BMI ) 18 30 kg/m2 inclusive Volunteers partner childbearing potential must use two medically approve method contraception ( e.g . hormonal contraception , IUD , barrier contraception ) , one must barrier method , duration study 3 month last drug administration If capable reproduction , unwilling use effective form contraception Suspicion regular consumption drug abuse Positive result hepatitis B ( HBV ) , hepatitis C ( HCV ) , HIV 1 2 Clinically relevant ECG abnormality screen Family history congenital long QT syndrome know congenital arrhythmia Systolic blood pressure great 140 less 90 mm Hg , diastolic blood pressure great 90 less 50 mm Hg . Resting Pulse Rate great 90 less 45 beat per minute Any clinical relevant clinical abnormality Participation investigational drug device study within 90 day prior screen Donation 500 mL blood within three month prior screen Concomitant disease condition could interfere , treatment might interfere , conduct study , would , opinion investigator , pose unacceptable risk volunteer study</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>